TCTR20180115001尚未招募未知
Intra-ocular pressure reduction efficacy and safety of generic latanoprost marketed in Thailand after switching from the original: a randomized open-labelled controlled trial
Bausch & Lomb Co., Ltd.0 个研究点目标入组 70 人开始时间: 2018年1月15日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 Years 至 80 Years（—）
- 性别
- All
入选标准
- •Patients who have been diagnosed with any type of glaucoma or ocular hypertension
- •No history of cataract within the last 3 months
- •Using the original latanoprost (Xalatan) for more than 4 weeks
排除标准
- •History of any type of intraocular pressure reduction surgery
- •History of laser peripheral iridotomy within the last 3 months
- •History of ocular trauma
- •Currently on more than 1 antihypertensive eyedrops apart from latanoprost
- •History of any irregular ocular surface condition
- •Currently on glucocorticoid eyedrops
研究者
相似试验
尚未招募
不适用
Effect of pressure reducing effect of Ripasudil eye drops in patients with high pressure within the eyeCTRI/2022/09/045191Sankara eye hospital
已完成
不适用
Evaluation of the Intraocular pressure lowering effect of Tafluprost and Latanoprost on normal tension GlaucomaGlaucomaJPRN-UMIN000002017Department of ophthalmology, Kyoto Prefectural University of Medicine30
已完成
不适用
Comparison of intraocular pressure lowering effects among four prostaglandin analogues: parallel administration to the bilateral eyes of normal subjects.glaucoma, ocular hypertensionJPRN-UMIN000003810Department of Ophthalmology, Houju Memorial Hospital25
已完成
不适用
A study of the intraocular pressure lowering effect of topical application of ripasudil in clinical practiceGlaucomaJPRN-UMIN000025466Kobe University Graduate School of Medicine130
已完成
3 期
A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI StudyPrimary Open Angle Glaucoma or Ocular HypertensionNCT02822742Santen Pharmaceutical Co., Ltd.26